Ecopipam Does Not Adversely Affect Metabolic Parameters in Pediatric Patients With Tourette Syndrome (TS): Results From a Phase 2b Randomized, Placebo-Controlled Trial (RCT) With a 12-Month Open-Label Extension (OLE)

被引：0

作者：

Gilbert, D. L.

Atkinson, S. D.

Karkanias, G. B.

Munschauer, F.

Wanaski, S.

Cunniff, T.

机构：

来源：

ANNALS OF NEUROLOGY | 2025年 / 96卷

关键词：

Experimental Therapeutics; Movement Disorders;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S62 / S62

页数：1

共 50 条

[41] RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS: EFFICACY AND SAFETY RESULTS FROM A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY (RM-131-009)
Camilleri, Michael
McCallum, Richard W.
Tack, Jan F.
Spence, Sharon C.
Gottesdiener, Keith
Fiedorek, Fred T.
GASTROENTEROLOGY, 2017, 152 (05) : S139 - S140
[42] Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
Reilhac, Caroline
Dubourg, Julie
Thang, Carole
Grouin, Jean-Marie
Fouqueray, Pascale
Watada, Hirotaka
DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 838 - 848
[43] Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Papp, Kim A.
Merola, Joseph F.
Gottlieb, Alice B.
Griffiths, Christopher E. M.
Cross, Nancy
Peterson, Luke
Cioffi, Christopher
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 277 - +
[44] Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial
Bondarde, S.
Kaklamani, V.
Sahoo, T. Prasad
Lokanatha, D.
Raina, V.
Jain, M.
Schwartzberg, L.
Gradishar, W. J.
CANCER RESEARCH, 2010, 70
[45] Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)
Bays, Harold E.
Ballantyne, Christie M.
Kastelein, John J.
Isaacsohn, Jonathan L.
Braeckman, Rene A.
Soni, Paresh N.
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (05): : 682 - 690
[46] Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled trial and open-label long-term extension
Howard, James F., Jr.
Nowak, Richard J.
Wolfe, Gil I.
Benatar, Michael G.
Duda, Petra W.
MacDougall, James
Farzaneh-Far, Ramin
Kaminski, Henry J.
NEUROLOGY, 2019, 93 (05) : E533 - E534
[47] EFFICACY AND SAFETY OF LESINURAD (RDEA594), A NOVEL URAT1 INHIBITOR, IN COMBINATION WITH ALLOPURINOL IN ALLOPURINOL-REFRACTORY GOUT PATIENTS: RESULTS FROM A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, PHASE 2B EXTENSION STUDY
Perez-Ruiz, F.
Sundy, J.
Krishnan, E.
Hingorani, V.
Welp, J.
Rodgers, T.
Manhard, K.
Cravets, M.
Hagerty, D.
Quart, B.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 439 - 439
[48] Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: Results from the ALLEGRO phase 2b/3, randomized, double-blind, placebo-controlled trial
King, Brett
Szepietowski, Jacek C.
Farrant, Paul
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
[49] Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial
Bingham, Clifton O., III
Mendelsohn, Alan M.
Kim, Lilianne
Xu, Zhenhua
Leu, Jocelyn
Han, Chenglong
Lo, Kim Hung
Westhovens, Rene
Weinblatt, Michael E.
ARTHRITIS CARE & RESEARCH, 2015, 67 (12) : 1627 - 1636
[50] Improvement in patient-reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial
Sinclair, Rodney
Mesinkovska, Natasha
Mitra, Debanjali
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69

← 1 2 3 4 5 →